Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514001 | 0.81 | ADORA2A (0.54) | ALDH1A1ADORA2APKMKMT2AL3MBTL1 | |
| SCHEMBL3832032 | 0.80 | ROCK2 (0.48) | CA12CA2CA9CA1CDK2 | |
| SCHEMBL14513998 | 0.75 | CDC7 (0.53) | CDK2ALDH1A1ADORA2APKMKMT2A | |
| SCHEMBL14514002 | 0.72 | ADORA2A (0.55) | P2RX4ALDH1A1ADORA2AKMT2AL3MBTL1 | |
| SCHEMBL3254956 | 0.70 | CLK4 (0.52) | CA12CA2CA9CA1CDK2 | |
| SCHEMBL5632430 | 0.70 | KDM4E (0.47) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL14513942 | 0.70 | KDM4E (0.47) | CA12CA2CA9CA1ALDH1A1 | |
| SCHEMBL14514018 | 0.68 | CA1 (0.54) | CA12CA2CA9CA1CDK2 | |
| SCHEMBL14513995 | 0.67 | KDM4E (0.61) | ALDH1A1KMT2ADYRK1ACLK4 | |
| SCHEMBL14372364 | 0.66 | P2RX4 (0.80) | P2RX4P2RX7ALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713793-A4 | PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | EP | claimed |
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HASEGAWA MASAICHI | 2007-05-24 | — | — | US | claimed |
| EP-1713793-A2 | PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS | Smithkline Beecham Corporation (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005076854-A2 | PYRIMIDINONE COMPOUNDS USEFUL AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | claimed |
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HASEGAWA MASAICHI | 2007-05-24 | — | — | US | disclosed |
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HASEGAWA MASAICHI | 2007-05-24 | — | — | US | disclosed |
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HASEGAWA MASAICHI | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117818-A1 | Pyrimidinone compounds useful as kinase inhibitors | HIPK3, HIPK1, HIPK2 | CA12 4885/4885CA2 4823/4885CA9 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.